Compare CMTL & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | NOTV |
|---|---|---|
| Founded | 1967 | 1974 |
| Country | United States | United States |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 12.4M |
| IPO Year | 2024 | 1997 |
| Metric | CMTL | NOTV |
|---|---|---|
| Price | $5.23 | $0.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $1.50 |
| AVG Volume (30 Days) | 296.0K | ★ 534.6K |
| Earning Date | 03-16-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | $499,528,000.00 | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | $1.97 | $5.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $1.19 | $0.25 |
| 52 Week High | $6.21 | $3.35 |
| Indicator | CMTL | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 35.87 |
| Support Level | $4.86 | $0.25 |
| Resistance Level | $6.15 | $0.65 |
| Average True Range (ATR) | 0.35 | 0.03 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 36.36 | 36.86 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.